Point looks to turn the tables on Novartis

Radiopharmaceuticals are a different beast versus traditional drugs. Just ask Novartis, which has endured problems supplying first Lutathera and now Pluvicto, issues that have marred an otherwise hugely successful launch of the latter drug and are set to keep it away from new patients for months.

In contrast, Point Biopharma tells Evaluate Vantage that it decided early on to focus on manufacturing before even building a pipeline – a controversial move that Novartis’s troubles seem to have vindicated. Now the two companies are heading for a showdown, with rival studies in prostate cancer set to read out in the second half.